148 related articles for article (PubMed ID: 34523851)
1. [New treatment for patients with therapy-resistant lymphoma: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy].
van Doesum JA; Niezink AGH; van Meerten T
Ned Tijdschr Geneeskd; 2021 Aug; 165():. PubMed ID: 34523851
[TBL] [Abstract][Full Text] [Related]
2. Concurrent remission of lymphoma and Sjögren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report.
Sheng L; Zhang Y; Song Q; Jiang X; Cao W; Li L; Yi H; Weng X; Chen S; Wang Z; Wu W; Wang L; Zhao W; Yan Z
Front Immunol; 2023; 14():1298815. PubMed ID: 38173731
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma].
Yu T; Liu H; Lei W; Chen PP; Zhao AQ; Yuan XG; Gao JM; Qian WB
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):820-824. PubMed ID: 38049333
[No Abstract] [Full Text] [Related]
4. [Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
Lu Y; Liu H; Ye SG; Zhou LL; Luo X; Dang XY; Yuan XG; Qian WB; Liang AB; Li P
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):813-819. PubMed ID: 38049332
[No Abstract] [Full Text] [Related]
5. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
Medina I; Carpio C; Ruiz-Camps I; Albasanz-Puig A; Lopez-Godino O; Esperalba J; Beas F; Sanchez-Salinas M; Iacoboni G; Barba P
Immunotherapy; 2023 Nov; 15(16):1369-1374. PubMed ID: 37718888
[TBL] [Abstract][Full Text] [Related]
6. [Current and future perspectives on CAR-T cell therapy to adult malignant lymphoma].
Shimoyama T
Rinsho Ketsueki; 2023; 64(9):1192-1202. PubMed ID: 37899200
[TBL] [Abstract][Full Text] [Related]
7. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy.
Ahmed N; Kumar A; Kharfan-Dabaja MA; DeFilipp Z; Herrera A; Hashmi S; Dholaria B; Perales MA; Carpenter PA; Hamadani M
Transplant Cell Ther; 2022 Sep; 28(9):523-529. PubMed ID: 35671986
[TBL] [Abstract][Full Text] [Related]
8. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Iacoboni G; Navarro V; Martín-López AÁ; Rejeski K; Kwon M; Jalowiec KA; Amat P; Reguera-Ortega JL; Gallur L; Blumenberg V; Gutiérrez-Herrero S; Roddie C; Benzaquén A; Delgado-Serrano J; Sánchez-Salinas MA; Bailén R; Carpio C; López-Corral L; Hernani R; Bastos M; O'Reilly M; Martín-Martín L; Subklewe M; Barba P
J Clin Oncol; 2024 Jan; 42(2):205-217. PubMed ID: 37874957
[TBL] [Abstract][Full Text] [Related]
9. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Yakoub-Agha I; Chabannon C; Bader P; Basak GW; Bonig H; Ciceri F; Corbacioglu S; Duarte RF; Einsele H; Hudecek M; Kersten MJ; Köhl U; Kuball J; Mielke S; Mohty M; Murray J; Nagler A; Robinson S; Saccardi R; Sanchez-Guijo F; Snowden JA; Srour M; Styczynski J; Urbano-Ispizua A; Hayden PJ; Kröger N
Haematologica; 2020; 105(2):297-316. PubMed ID: 31753925
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma.
Hayashino K; Seike K; Fujiwara K; Kondo K; Matsubara C; Terao T; Kitamura W; Kamoi C; Fujiwara H; Asada N; Nishimori H; Ennishi D; Fujii K; Fujii N; Matsuoka KI; Maeda Y
Int J Hematol; 2024 Apr; 119(4):459-464. PubMed ID: 38349446
[TBL] [Abstract][Full Text] [Related]
11. Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma.
Newsam AD; Coughlin CA; Trabolsi A; Schatz JH
Leuk Lymphoma; 2023 Dec; 64(14):2217-2224. PubMed ID: 37933565
[TBL] [Abstract][Full Text] [Related]
12. Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
Boyle S; Roddie C; O'Reilly M; Menne T; Norman J; Gibb A; Lugthart S; Chaganti S; Gonzalez Arias C; Jones C; Latif A; Uttenthal BJ; Seymour F; Osborne W; Springell D; Hardefeldt P; Yallop D; Thoulouli E; Bloor A; Besley C; Mathew A; Burns D; Cwynarski K; Sanderson R; Kuhnl A
Br J Haematol; 2024 Feb; 204(2):507-513. PubMed ID: 37848384
[TBL] [Abstract][Full Text] [Related]
13. Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy.
Qian H; Yang X; Zhang T; Zou P; Zhang Y; Tian W; Mao Z; Wei J
Am J Hematol; 2024 Apr; 99(4):662-678. PubMed ID: 38197307
[TBL] [Abstract][Full Text] [Related]
14. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study.
Wang J; Alkrekshi A; Dasari S; Lin HC; Elantably D; Armashi ARA
Bone Marrow Transplant; 2023 Nov; 58(11):1223-1228. PubMed ID: 37604871
[TBL] [Abstract][Full Text] [Related]
15. Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
Chohan KL; Bansal R; Hathcock MA; Paludo J; Bennani NN; Johnston PB; Khurana A; Durani U; Wang Y; Ruff MW; Villasboas Bisneto JC; Ansell SM; Lin Y; Kenderian SS
Leuk Lymphoma; 2024 Mar; 65(3):389-393. PubMed ID: 38031734
[No Abstract] [Full Text] [Related]
16. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma.
Jain MD; Ziccheddu B; Coughlin CA; Faramand R; Griswold AJ; Reid KM; Menges M; Zhang Y; Cen L; Wang X; Hussaini M; Landgren O; Davila ML; Schatz JH; Locke FL; Maura F
Blood; 2022 Aug; 140(5):491-503. PubMed ID: 35476848
[TBL] [Abstract][Full Text] [Related]
17. CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach.
Dreger P; Corradini P; Gribben JG; Glass B; Jerkeman M; Kersten MJ; Morschhauser F; Mussetti A; Viardot A; Zinzani PL; Sureda A;
Lancet Haematol; 2023 Dec; 10(12):e1006-e1015. PubMed ID: 38030311
[TBL] [Abstract][Full Text] [Related]
18. Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
Ahmadi P; Ghandili S; Jakobs F; Konnopka C; Morgner-Miehlke A; Kröger N; Ayuk F
Bone Marrow Transplant; 2024 Apr; 59(4):572-574. PubMed ID: 38321270
[No Abstract] [Full Text] [Related]
19. Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
Crombie JL; Jacobson CA; Redd R; Shouse G; Herrera AF; Chow VA; Gauthier J; Mullane E; Cahill K; Kline J; Romancik J; Cohen JB; Saucier A; Houot R; Armand P; Hess B
Haematologica; 2023 Dec; 108(12):3433-3437. PubMed ID: 37259597
[No Abstract] [Full Text] [Related]
20. Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy.
Ababneh HS; Frigault MJ; Patel CG
Hematol Oncol; 2024 Jan; 42(1):e3221. PubMed ID: 37679941
[No Abstract] [Full Text] [Related]
[Next] [New Search]